NCT06925542招募中1 期
A Phase 1 Dose Evaluation Study of the Safety and Preliminary Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX112) in Adult Subjects With Refractory Autoimmune Disease
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 80
- 试验地点
- 28
- 主要终点
- To evaluate the safety of CTX112 in adult subjects with refractory autoimmune diseases, including SLE, SSc or IIM
研究概览
简要总结
This is a single-arm, open-label, multicenter, ascending dose Phase 1 study evaluating the safety and preliminary efficacy of CTX112 in adult subjects with refractory autoimmune diseases, including active systemic lupus erythematosus (SLE), systemic sclerosis (SSc), or idiopathic inflammatory myopathy (IIM).
详细描述
This study may enroll up to 80 subjects in total. CTX112 is a CD19 directed chimeric antigen receptor (CAR) T cell immunotherapy comprised of allogeneic T cells prepared for the treatment of refractory autoimmune diseases. The cells are from healthy adult volunteer donors that are genetically modified ex vivo using CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats/ CRISPR-associated protein 9) gene editing components (single guide RNA and Cas9 nuclease).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥18 years and < 70 years of age.
- •Subjects must voluntarily sign a written informed consent and be willing and able to comply with all study requirements.
- •Adequate hematologic, renal, liver, cardiac and pulmonary organ function.
- •Subjects must agree to use acceptable methods of contraception.
- •Willing and able to comply with scheduled visits, treatment plan, laboratory tests, contraceptive guidelines, and other study procedures.
- •Diagnosis of systemic lupus erythematosus (SLE), systemic sclerosis (SSc) or idiopathic inflammatory myopathy (IIM).
- •For systemic lupus erythematosus (SLE) subjects:
- •- Diagnosis of SLE by a board-certified rheumatologist that conforms with 2019 ACR/EULAR criteria. For lupus nephritis subjects, active, biopsy-proven proliferative lupus nephritis Class III or IV, either with or without the presence of Class V, and appropriate National Institutes of Health index activity score using the 2018 International Society of Nephrology/Renal Pathology Society criteria.
- •For Systemic Sclerosis (SSc) subjects:
- •- Diagnosis of diffuse cutaneous systemic sclerosis (dcSSC) or SSc-ILD that conforms with 2013 ACR/EULAR criteria. Subjects should meet active skin or lung disease criteria.
- •For Idiopathic Inflammatory Myopathy (IIM) subjects:
- •- Diagnosis with dermatomyositis (DM), polymyositis (PM) or myositis as part of rheumatologic overlap syndrome, antisynthetase (ASyS), or immune-mediated necrotizing myopathy (IMNM) that conforms with 2017 ACR/EULAR criteria for inflammatory myopathies. Subjects must meet moderate severe, skin, or lung involvement criteria.
排除标准
- •Prior anti-CD19 therapy or any gene therapy/genetically modified cell therapy.
- •Prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant.
- •Severe active or history of central nervous (CNS) involvement.
- •History of a seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease or any autoimmune disease with CNS involvement other than SLE, SSc or IIM.
- •Mixed connective tissue disease with no clear predominant disease.
- •Presence of study disease manifestations or other conditions that are likely to pose increase safety risks and/or confound disease assessments, or pose significant risk to those receiving CAR T cell therapy.
- •History of primary or secondary immunodeficiency.
- •Presence or history of certain bacterial, viral or fungal infection.
- •Malignancy in the last 5 years (with the exception of cancers deemed to be low likelihood for recurrence).
- •Diagnosis of a genetic disorder associated with bone marrow failure or myelodysplastic syndrome.
- •History or current diagnosis of catastrophic anti-phospholipid syndrome or anti phospholipid syndrome that requires ongoing anticoagulation.
- •Pregnant or lactating.
- •Presence or history of disease requiring treatment that is not compatible with the study protocol; presence or history of other conditions that are not compatible with the study protocol.
研究组 & 干预措施
CTX112
Experimental
Administered by IV infusion following lymphodepleting chemotherapy
干预措施: CTX112 (Biological)
结局指标
主要结局
To evaluate the safety of CTX112 in adult subjects with refractory autoimmune diseases, including SLE, SSc or IIM
时间窗: From CTX112 infusion up to 28 days post-infusion
Incidence of dose-limiting toxicities
次要结局
- To assess the pharmacodynamic response of CTX112 in adult subjects with refractory autoimmune diseases, including SLE, SSc or IIM(From CTX112 infusion up to 60 months post-infusion)
- To assess the pharmacokinetics (PK) of CTX112 in adult subjects with refractory autoimmune diseases, including SLE, SSc or IIM(From CTX112 infusion up to 60 months post-infusion)
- To assess the preliminary efficacy of CTX112 in adult subjects with refractory autoimmune diseases, including active SLE, SSc or IIM.(From CTX112 infusion up to 60 months post-infusion)
研究者
研究点 (28)
Loading locations...
相似试验
终止
1 期
NK Cell Therapy for AMLAMLNCT05256277Zhejiang University3
招募中
1 期
To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)Gastric CancerNCT05514158RemeGen Co., Ltd.24
已完成
1 期
Evaluate Safety, Tolerability and Pharmacokinetics of HLX22 in Patients With Advanced Solid Tumors Overexpressing HER2Solid TumorNCT03916094Shanghai Henlius Biotech11
Unknown
1 期
A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Anti-PD-1 Antibody (HLX10) in Combination With Avastin Biosimilar (HLX04) in Patients With Advanced Solid TumorsSolid TumorNCT03757936Shanghai Henlius Biotech30
招募中
1 期
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BPI-21668Advanced Solid TumorNCT05341570Betta Pharmaceuticals Co., Ltd.60